Cryptotanshinone interferes with chondrocyte apoptosis in osteoarthritis by inhibiting the expression of miR‑574‑5p

隐丹参酮通过抑制 miR-574-5p 的表达来干扰骨关节炎中的软骨细胞凋亡

阅读:7
作者:Songtao Yue, Xiaochuan Su, Junyan Teng, Jiangyi Wang, Malong Guo

Abstract

Chondrocyte apoptosis is an important factor in the development and progression of osteoarthritis (OA). Cryptotanshinone (CTS) can inhibit chondrocyte apoptosis, but the specific mechanism remains unknown. The aim of the present study was to explore how CTS may affect chondrocyte apoptosis. Reverse transcription‑quantitative PCR and western blotting were used to validate microRNA (miR)‑574‑5p, YY1‑associated factor 2 (YAF2), Bcl‑2 and Bax expression levels. H&E, Safranin O and TUNEL staining assays were used to evaluate the apoptosis of arthritic chondrocytes in vivo. A Cell Counting Kit‑8 assay and flow cytometry were performed to detect cell proliferation and apoptosis of chondrocytes in vitro. The methylation level of the miR‑574‑5p promoter was measured via methylation specific PCR. The degree of chondrocyte apoptosis and the expression levels of YAF2 and Bcl‑2 were decreased in the mice with OA, and were increased in the OA + CTS mice, while the expression levels of miR‑574‑5p and Bax showed opposite changes. Furthermore, the degree of chondrocyte apoptosis and the expression levels of the aforementioned key factors in chondrocytes were consistent with those observed in vivo. The methylation degree of the miR‑574‑5p promoter was increased by the addition of CTS, and was reduced after the addition of a methylation inhibitor, 5‑aza‑CdR, indicating that CTS could regulate the methylation of miR‑574‑5p promoter. The present study suggested that CTS could downregulate the expression of miR‑574‑5p by regulating its methylation, and thus, could improve YAF2 expression and affect chondrocyte apoptosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。